Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema

Inclusion Criteria: * Patient, male or female (under effective contraception if premenopausal) over 18 years old * Patient affiliated with a social security plan * Patient able to understand and follow the instructions of the study * Patient having signed an informed consent * Patient having a central macular thickness greater than 320μm (Spectral Domain, 270µm Time Domain) * Patient with an inflammatory macular edema, unilateral or bilateral (in the case of a bilateral inflammatory macular edema, the eye most affected will be treated) Exclusion Criteria: * Patient with an infectious uveitis * Patient with uncontrolled active infection * Patient receiving an unbalanced general anti-inflammatory and/or immunosuppressive and/or immunomodulatory therapy (recent modification \<1 month) * Patient having a history of glaucoma and/or ocular hypertension in the eye studied (intraocular pressure (IOP) \> 25 mmHg without antiglaucoma medication or \> 21 mmHg with antiglaucoma combination therapy) and/or cortisone-causing-hypertension not controlled by an antiglaucoma dual therapy * Patient with uncontrolled diabetes (HbA1c\> 8%) or unbalanced hypertension (Systolic Blood Pressure \> 160 mmHg and/or Diastolic Blood Pressure \> 100mmHg) * Edematous diabetic maculopathy * Patient who had received triamcinolone (subconjunctivally or sub-tenon) 3 months before randomization, or 700μg dexamethasone intravitreally 6 months before randomization * Suspected or active ocular or periocular inf…